Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Advances in the Management of BPH
Current Opinion in Urological Cancer
PSA: Fact or Fiction The debate as it stands
Prostate Cancer What a GP Needs to Know
Diffusion-Weighted Imaging in Magnetic Resonance Imaging for prostate gland in Malaysian males with high prostate specific antigen in the diagnosis of.
A Case Study GP Masterclass Catherine Dale, RN, BSc Cancer Care
HEALTHY PEOPLE. Aims  Interpret evidence about a screening programme and decide whether it is worthwhile – for individuals or groups  Demonstrate an.
Audit of Impact of NICE guidelines for Ovarian Cancer Helen Losty Royal United Hospital Bath 17th November 2011.
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Rising PSA after Radical Prostatectomy. My Approach. Dr Manish Patel Urological Cancer Surgeon Urological Cancer Surgeon Westmead Hospital University of.
Prostate Cancer Genetics and Diagnosis
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.
Prostate Cancer One of the commonest causes of death in the Western World USA 2005 – 232,090 new cases – 30,350 deaths Lifetime risk of disease 16.6% Lifetime.
Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.
Geriatric Health Maintenance: Cancer Screening Linda DeCherrie, MD Geriatric Fellow Mount Sinai Hospital.
PSA & Prostate Cancer Dan Burke Consultant Urological Surgeon
PROGRESS IN MANAGEMENT OF PROSTATE CANCER Presented by Dr. J. Nkusi on the October 2007, 38 th Congress of the Botswana Medical Association.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Prostate Cancer Screening Assistant Professor Charles Chabert Men’s health Seminar Ballina April 2011 prostates.com.au.
M Ravanbod Medical oncologist Bushehr – 11/91 A 50 y/o white man comes for check up and wants to discuss about prostate cancer. Negative family history.
Professor Abhay Rane OBE
How to manage suspected cancer
Prostate Cancer James B. Benton,M.D.. Prostate Cancer Significant of the clinical problem Early detection/screening Prevention/Management.
Should I have that blood test for Prostate Cancer?
Prostate Cancer Case Presentation Shireen Siddiqui.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.
Urology Update Sanofi- Aventis
Prostate Cancer Prostate cancer is the most common cancer detected in American men. The lifetime risk of a 50-year-old man for latent CaP is 40%; for.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
PSA Shared Care Jim Wood. Background A significant number of men with prostate cancer (CaP) are receiving regular hospital follow up (out- patient visits),
Better Health. No Hassles. Prostate Cancer Month Sokan Hunro, PAC, MPH.
MRI-Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department Department of Radiation Oncology.
Ten Year Outcomes In Men Under 60 Treated With Iodine-125 Permanent Brachytherapy As Monotherapy GU - Prostate Cancer: Novel Imaging (MRI,PET) & Brachytherapy.
“Prostate Cartography”: Targeted &systematic perineal stereotactic prostate biopsy using the BiopSee®platform in locating and re-locating prostate cancer.
Prostate Cancer Screening Risk Management Ben Inch.
Prostate Screening in the New Millennium Dr Pamela Ajayi MD PathCare.
Slainte an Chlar Health Education Day Cancer 20 th Feb 2010.
بسم الله الرحمن الرحيم. The role of three dimensional transrectal ultrasonography (3-D TRUS) and power Doppler sonography in prostatic lesions evaluation.
MpMRI in Prostate cancer A Urologist’s Perspective Diagnosis Treatment Choice Surgical Planning Dr. Peter Heathcote, Adjunct Professor APCRC-Q QUT, Senior.
Active surveillance in prostate cancer Dr John Yaxley Urological & robotic surgeon.
NICE GUIDELINES FOR SUSPECTED CANCER: RECOGNITION AND REFERRAL JUNE 2015 UROLOGY SSG MEETING 15 October 2015 Jamal Ghaddar, Matthew Goh Department of Urology.
V. Scattoni Biopsia ecoguidata. Bioptic strategies: targerted biopsy.
V. Scattoni mpMRI of the prostate: Does it change indications for biopsy and repeat biopsy?
Prostate Cancer Screening Who needs it?... and who doesn’t. Presented by: Michael K. Yu, MD.
Life after Prostate Cancer and its treatment Mr Sanjeev Pathak Consultant Urological Surgeon and Cancer Lead Doncaster and Bassetlaw NHS Trust 12 th March.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
Prostate Cancer David Eedes 11 May Prostate Cancer Definition: Prostate cancer is a disease in which cells in the prostate gland become abnormal.
Early Diagnosis of Gynaecological Cancer Rob Gornall Consultant Gynaecology GHNHST.
Manit Arya Consultant Urological Surgeon UCLH and PAH Transforming the Pathway in Prostate Cancer.
PSA Consensus and The Prostate Cancer Risk Management Programme Karen Stalbow, Prostate Cancer UK Dr Ali Cooper, Prostate Cancer UK Annual Conference 2016.
Screening for Prostate Cancer
Network meeting Taunton Rugby club January 20th
PSA, PCA-3 and peace of mind in suspected prostate cancer
Prostate Cancer Dr .Gehan Mohamed.
What would you recommend?
Definition of Cancer Screening
PSA testing.
Prostate Cancer: Highlights from 2006
Prostate Cancer Screening- Update
Volume 62, Issue 1, Pages (July 2012)
Volume 67, Issue 4, Pages (April 2015)
Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions  Anwar R. Padhani, Jeffrey Weinreb, Andrew.
Prostate Cancer Update
Standardised follow-up
Maintaining bone health while on ADT for Prostate Cancer
Introduction European Urology Supplements
Prostate cancer screening beyond PSA – STHLM3 and/or MRI
Presentation transcript:

Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital

Agenda  Suspected cancer referral update  Management of PSA.  What is new about prostate cancer  Prostate cancer management update  Primary care management  Secondary care management

When to do PSA  After the age of 50 yrs  Do earlier (40 yrs) if family history and Afro-Caribbean descent.  Consider PSA and DRE in patients with  Any LUTS (nocturia/frequency/retention/hesitency/urgency)  ED  Visible Hematuria

Suspected cancer referrals: urology NICE 2015  PSA above the age specific range.  Malignant feeling prostate on DRE : refer under 2 week pathway  Hard/firm feeling prostate, hard nodule

Prostate cancer  41K new cases of prostate cancer each year in the UK, so a full time GP will diagnose one new person with prostate cancer each year.  134 new cancers /100,000 men.  10K die each year from prostate cancer in UK  5 Yr survival is 80%

Clinical symptoms  Presenting complaintsPPV  LUTS (voiding/storage)  Hematuria1.8%  ED  Disseminated disease.  Nocturia + abn DRE15%  Loss of weight + nocturia12%  Loss of weight + BPH on DRE9.4%

PSA facts  PSA between 3-10 only 20% have cancer on biopsy  PSA >10 upto 50% risk of cancer  Screening: currently not supported by all organisations  13 year follow up from ERSPC shows a 0.11 reduction of death from caP per 1000 person years. 1 caP death averted in 781 screened and 27 additional caP detected.

Other PSA related parameters  PSA density (prostate volume)  PSA velocity.  PSA doubling time.

Baseline PSA at yrs  Early PSA between 40 and 45yrs has a potential to predict risk of advanced caP 30 yrs later.  If the PSA is <1 then low risk and only repeat 8yrs later.  PSA >1.4 to monitor more closely.

What is new in the diagnosis of prostate cancer  TRUS biopsy of the prostate :  Multiparametric MRI of the prostate to identify lesions more accurately.  Increased characterization of the lesions  PIRAD scoring system  Improved accuracy of biopsy targeting using fusion software.

Background  Peripheral zone 70 %  Central zone 25%  Transitional zone 5%

TRUS vs transperineal biopsy prostate  Accessing peripheral zone.  Misses 12-15% of cancer.  Only targeting through ultrasound and hence ‘blind’.

NICE guidance CG 175  Magnetic resonance imaging for rebiopsy  Consider multiparametric MRI (using T2- and diffusion-weighted imaging) for men with a negative transrectal ultrasound 10–12 core biopsy to determine whether another biopsy is needed. [new 2014]  Do not offer another biopsy if the multiparametric MRI (using T2- and diffusion-weighted imaging) is negative, unless any of the risk factors listed in recommendation are present. [new 2014]

Risk factors in patients with negative TRUS biopsy.  Men who have had a negative first prostate biopsy still has a risk that prostate cancer is present and  the risk is slightly higher if any of the following risk factors are present:  The biopsy showed high-grade prostatic intra-epithelial neoplasia (HGPIN)  The biopsy showed atypical small acinar proliferation (ASAP)  Abnormal digital rectal examination. [new 2014]

MRI pre biopsy  263 consecutive patients with suspicion of prostate cancer were investigated.  All had 3-T multiparametric MRI (mpMRI) applying the European Society of Urogenital Radiology criteria.  All patients underwent MRI/US-fusion biopsy transperineally (mean nine cores) and additionally a systematic transrectal biopsy (mean 12 cores).

Benefit of MRI to target  Abnormality on MRI is common.  Significant abnormality is in central and ventral area NOT accessible by TRUS.  45% (69/154) peripheral zone  37% (57/154) central zone  18% (28/154) ventral zone of the prostate All Without previous biopsy Repeat biopsy Number of patients Lesions, n PI-RADS on mpMRI, n (%) PI-RADS < 286 (18.9)22 (20)64 (18.6) PI-RADS 3183 (40.3)31 (28.2)152 (44.2) PI-RADS 4135 (29.8)44 (40)91 (26.4) PI-RADS 550 (11.0)13 (11.8)37 (10.8)

Benefit of MRI to target All Without previous biopsy Repeat biopsy Number of patients Lesions, n Men with proven prostate cancer, n (%) Overall137 (52)35 (52)102 (52) Targeted biopsy 116 (44)31 (46)85 (44) Systematic biopsy 91 (34)29 (43)62 (32)  More lesions noted per patient  More cancers in targeted transperineal biopsy 44% vs standard TRUS biopsy34%.  We may have to do both to be able to get best outcomes.  First biopsy the difference is small.

 MRI/US-fusion biopsy detected significantly more cancer than systematic prostate biopsy (44% [116/263] vs 35% [91/263]; P = 0.002).  In first biopsy, the detection rate was 46% (31/68) in targeted and 43% (29/68) in systematic biopsy (P = 0.527).

Treatment of prostate cancer.  Localised prostate cancer:  Active surveillance  Radical retropubic prostatectomy  Robotic  Laparoscopic  Open.  Radical radiotherapy  Brachy therapy  Locally advanced prostate cancer  Metastatic prostate cancer.  Management of hormone resistant prostate cancer.

When to do active surveillance

Management of prostate cancer in primary care  Raised PSA and negative prostate biopsy:  Active surveillance  Stable prostate cancer in metastatic prostate cancer.

Stable metastatic prostate cancer  Hormone treatment  Zoladex/ prostap/  Intermittent hormone treatment.  Monitor PSA Q 3 mo  Restart if PSA >10

Summary  PSA remains the marker of choice.  PPV increases with loss of weight, abnormal DRE +/- LUTS  MRI helps to identify areas of the prostate that are suspicious and allows targeted biopsy and may influence treatment.  Active surveillance is a suitable option in low risk prostate cancer.  Primary care management of patients with stable metastatic prostate cancer on hormone treatment.

Questions please?